CCA
NRIX icon

Cygnus Capital Advisors’s Nurix Therapeutics NRIX Stock Holding History

Cygnus Capital Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51 Buy
+3,300
New +$54.7K 0.03% 73

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Cygnus Capital Advisors's NRIX Position: Q1 2026 in Review

Cygnus Capital Advisors opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 3,300 shares worth $51. The stake represents 0.03% of the portfolio and ranks #73 among its holdings.

196 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Cygnus Capital Advisors held 3,300 shares of Nurix Therapeutics worth $51 as of Q1 2026.
  • Nurix Therapeutics was a new Cygnus Capital Advisors position in Q1 2026.
  • Nurix Therapeutics made up 0.03% of Cygnus Capital Advisors's portfolio in Q1 2026, its #73 holding.
  • 196 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.